新型药物时代下含抑制物血友病旁路制剂的前景
综述指出旁路制剂目前仍是高滴度抑制物血友病患者出血治疗和预防的标准治疗,但可选品种有限,仅活化凝血酶原复合物和重组凝血因子VIIa。艾美赛珠单抗等非因子疗法正在发展,未来旁路制剂使用可能减少,但在可预见的未来仍不可或缺,其临床开发仍在继续。
要点
- 旁路制剂目前是含高滴度抑制物血友病患者出血治疗和预防的标准治疗。
- 仅两种旁路制剂可用,分别源自1970年代的活化凝血酶原复合物和1980年代的重组凝血因子VIIa。
- 艾美赛珠单抗等非因子疗法正在发展,但旁路制剂在可预见的未来仍不可或缺。
核心结论
- 旁路制剂目前是含高滴度抑制物血友病患者出血治疗和预防的标准治疗,仅两种产品可用。
- 随着非因子疗法更广泛使用,旁路制剂的使用可能预期减少,但在可预见的未来旁路制剂仍不可或缺。
- 旁路制剂的临床开发仍在继续,部分产品(如eptacog beta)正在接受监管审评。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- 目前可用的旁路制剂仅有两种,分别追溯至1970年代的活化凝血酶原复合物和1980年代的重组凝血因子VIIa。
- 临床医生依靠经验、观察性经验、登记数据和个体化医疗来改善患者的临床结局。
- 艾美赛珠单抗是双特异性抗体,模拟FVIIIa在内在Xase复合物中的功能,适用于抑制物患者每周一次或每两周一次的预防性给药。
- 其他在研非传统产品包括fitusiran和靶向组织因子途径抑制物的抗体。
关键数值与推荐
- 艾美赛珠单抗适用于抑制物患者每周一次或每两周一次的预防性给药。
- 旁路制剂目前是含高滴度抑制物血友病患者出血治疗和预防的标准治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bypassing agents are presently the standard of care for the treatment of bleeding episodes in patients with hemophilia and high-titer inhibitors and are also used for bleed prevention. Only two bypassing agents are available to patients, and these products trace their lineage to the 1970s (activated prothrombin complex concentrates) and the 1980s (recombinant factor VIIa). Given the limited repertoire of available products, clinicians have relied on experience, empirical observation, registry data and individualized care to improve clinical outcomes on a case-by-case basis. Research over the past two decades has culminated in a greatly improved understanding of human coagulation; resulting from this, new products have been developed that offer treatment options and mechanisms of actions that differ from current bypassing agents. The most advanced in clinical development is emicizumab, a bispecific antibody that mimics the function of FVIIIa in the intrinsic Xase complex and is indicated for once-weekly or every-other-week prophylactic dosing in inhibitor patients. Other non-traditional products in clinical development include fitusiran and antibodies directed against tissue factor pathway inhibitor. As non-factor-based therapies become more widely utilized over time, the use of bypassing agents may be expected to decrease; however, bypassing agents will remain essential for the foreseeable future. As such, clinical development of bypassing agents continues, with some products (e.g. eptacog beta) under regulatory review. In this review we examine the optimal use of bypassing agents and their mechanism of action. We also discuss newer products and how these might theoretically be administered in conjunction with traditional bypassing agents.
引用
- Shapiro AD, Mitchell IS, Nasr S, et al. The future of bypassing agents for hemophilia with inhibitors in the era of novel agents. J Thromb Haemost. 2018. PMID: 30264916. doi:10.1111/jth.14296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。